Skip to main content
. Author manuscript; available in PMC: 2021 Feb 12.
Published in final edited form as: Biochem Biophys Res Commun. 2019 Nov 28;522(3):633–638. doi: 10.1016/j.bbrc.2019.11.130

Fig.3. Selective effects of PF-04859989 on PDA cells.

Fig.3

Viability dose-response curves for PF-04859989 on (a) PATU-8988T, (b) PATU-8902, and (c) IMR-90. Relative ROS levels in (d) PATU-8902 or (e) IMR-90 cells in the presence of Gln-free media or PF-04859989. Relative (f) aspartate or (g) malate levels in PATU-8902 cells in the presence of PF-04859989. (h) IC50 (μM) of PF-04859989 against purified GOT1, GOT2 or KAT2 in enzymatic assays with 24 hours of pre-incubation with PF-04859989. (i) Relative cell viability of PATU-8902 cells treated with PF-04859989 (25 μM) (blue line), with supplementation of OAA (2 mM) (green line) or kynurenate (2 mM) (orange line). Data are mean of n=3 determinations +/− S.D.